Acumen Research and Consulting recently published report titled “Male Infertility Market Size, Share, Analysis Report and Region Forecast, 2022 – 2030”
SEATTLE, June 22, 2022 (GLOBE NEWSWIRE) — The Global Male Infertility Market size accounted for USD 3,834 Mn in 2021 and is estimated to reach USD 5,885 Mn by 2030, with a significant CAGR of 5.0% from 2022 to 2030.
The Urology Health data states that about 13 out of 100 couples can’t get pregnant. According to the American Society of Reproductive Medicine (ASRM), about one-third of infertility cases are caused by males. The female is the third. In the last third of infertile couples, the disorder is faced by a mix of factors, or it cannot be explained in 20 out of 100 cases. The occurrence of infertility varies, and male infertility is less well reported in developing nations. Because of limited medical resources and expensive treatment costs, as well as cultural anxieties, taboos, and stigmas, the burden of infertility is often greater in developing countries.
Request for a free sample report @
|Market||Male Infertility Market|
|Market Size 2021||USD 3,834 Mn|
|Market Forecast 2030||USD 5,885 Mn|
|CAGR During 2022 – 2030||5.0%|
|Analysis Period||2018 – 2030|
|Forecast Data||2022 – 2030|
|Segments Covered||By Test, By Treatment, By End-User, By Region|
|Regional Scope||North America, Europe, Asia Pacific, Latin America, and Middle East & Africa|
|Key Companies Profiled||Andrology Solutions, Halotech DNA SL, AytuBioScience, Inc., Bayer Healthcare, EMD Sereno, Inc., Cadila Healthcare Ltd., SCSA Diagnostics, Inc., and Intas Pharmaceuticals Ltd.|
|Report Coverage||Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis|
|Customization Scope||10 hrs of free customization and expert consultation|
Changing Lifestyle is One of the Leading Reasons for Male Infertility
Male infertility is a common problem among couples. Couple infertility is caused by the male partner in approximately 50% of cases, primarily due to spermatogenesis failure. As male fertility can be impacted by a lot of factors, one plausible cause for the declining trend is that environmental and/or occupational factors, as well as lifestyle practices, contribute to the deterioration of sperm quality. Multiple factors, such as paternity age, nutrients, physical activity, obesity, caffeine, scrotal temperature, clothing, hot water, and mobile phones can all have an impact on the quality of life of sperm parameters and DNA damage caused by reactive oxygen species (ROS). Thus, lifestyle modification through a structured program of environmental, educational, nutritional/physical exercise, and psychological support, coupled with the use of nutraceuticals antioxidants, can help couples obtain better outcomes and improve their chances of conceiving spontaneously or optimize their chances of conception.
Check the detailed table of contents of the report @
COVID-19 Impact on Male Infertility Industry
The SARS-CoV-2 virus’s clinical disease, COVID-19, has been linked to a massive organ system destruction and cytokine storm. According to researchers, COVID-19 may affect sperm quality by reducing fertility in men, with the intensity of the effect depending on the severity of the disease. Regardless of the evidence for SARS-CoV-2 virus infection in the testicles, some studies have found testicular injury and gonadotropin dysregulation linked to inflammation. Despite the fact that there were cases of infertility, there was a decrease in its treatment. Since, only emergency treatment have been allowed to operate during the pandemic, the male infertility treatment was hampered a lot.
High Cost of Male Infertility Procedures Could Hamper the Growth
The cost of a varicocelectomy ranges from 3290 to 6590 USD, while testicular sperm extraction ranged from 1640 to 3290 USD. It is estimated that patients spent about 18% of their annual income on infertility care on average, excluding major surgeries. In the United States, the National Survey of Family Growth discovered that 18%–27% of men seeking infertility treatment do not complete all evaluation procedures. A recent study, on the other hand, discovered that family income is a key obstacle in the management of male infertility. The cost of male infertility diagnosis and treatment is very high, and it is a significant barrier, even for high-income couples. Furthermore, according to the World Health Organization and the American Society of Reproductive Medicine (ASRM), private companies rarely provide insurance coverage for infertility treatments. Increasing access to and use of male reproductive health strategies may thus improve outcomes of this health issue.
Rising Technological Advancements in Infertility Treatments Boost the Male Infertility Market Revenue
Infertility is a common condition that affects a projected 70 million people worldwide. The World Health Organization reported that 9% of couples worldwide suffer from fertility issues, with men accounting for 50% of the problems. Male infertility treatment strategies have evolved dramatically over the last decade. These advancements are largely due to microsurgical varicocelectomy as well as microsurgical procedures for ART and surgical sperm retrieval, specifically ICSI. Microsurgical varicocelectomy increased sperm retrieval rate significantly in patients with clinical varicocele and non-obstructive azoospermia (NOA); it may also be a treatment option for subclinical varicocele. On top of that, increasing number of research & development activities to find better drugs and treatments has allowed the industry to spur throughout the coming years.
Male Infertility Market Segmentation
The global male infertility market has been segmented based on test, treatment, end-user, and geography. Based on the test, the market is divided into oxidative stress analysis, DNA fragmentation technique, sperm agglutination, microscopic examination, sperm penetration assay, computer-assisted semen analysis, and others. Among them, the DNA fragmentation technique segment generated the largest male infertility market revenue, while the computer-assisted semen analysis test attained the fastest growth rate all over the forecast period 2022 – 2030.
Medication and assisted reproductive technology and varicocele surgery are the bifurcations of the treatment segment. Based on our analysis, the assisted reproductive technology and varicocele surgery segment achieved the largest market share in 2021.
By end-user, the market is split into fertility centers, hospitals and clinics, research institutes, and others. In 2021, fertility end-users occupied the majority of the male infertility market share. In addition, fertility centers are expected to attain the fastest growth rate in the coming years.
Male Infertility Market Regional Overview
North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa are the regional classification of the global male infertility market. Based on our analysis, the Europe region dominated the market with utmost shares during the forecast timeframe from 2022 to 2030. The region’s rapid growth can be attributed to the widespread use of more expensive treatments, as well as the availability of well-equipped and advanced fertility clinics. Cigarette use affects nearly 37% of men of reproductive age, and Europe has the largest tobacco use amongst all World Health Organization regions. Meanwhile, the Asia-Pacific region is anticipated to witness the fastest CAGR in the coming years. The Asia-Pacific male infertility market is being driven by advances in medical diagnostics as well as rising awareness regarding the disorder.
Buy this premium research report –
Key players covered globally in Andrology solutions, Halotech DNA SL, AytuBioScience, Inc., Bayer Healthcare, EMD Sereno, Inc., Cadila Healthcare Ltd., SCSA Diagnostics, Inc., and Intas Pharmaceuticals Ltd.
Browse More Research Topics on Healthcare and Pharmaceuticals Industry:
The Global Human Chorionic Gonadotropin Market size accounted for USD 874 Mn in 2020 and is expected to reach USD 1,534 Mn by 2028 with a considerable CAGR of 7.4% during the period of 2021 to 2028.
The Global Pharmaceutical Glass Packing Market is expected to grow at a CAGR of around 5.3% from 2020 to 2027 and expected to reach the market value of around USD 33.2 Bn by 2027
The Global Pharmaceutical Logistics Market size value at USD 133 Bn in 2027 and is expected to expand at a compound annual growth rate (CAGR) of 9.0% from 2020 to 2027.
About Acumen Research and Consulting:
Acumen Research and Consulting is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact-based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.
Mr. Richard Johnson
Acumen Research and Consulting
E-mail: [email protected]
Powered by WPeMatico